199 related articles for article (PubMed ID: 8815009)
1. Recombinant antibody fusion proteins for cancer immunotherapy.
Reisfeld RA; Gillies SD
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
[No Abstract] [Full Text] [Related]
2. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818
[TBL] [Abstract][Full Text] [Related]
3. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
4. Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice.
Qi Y; Moyana T; Bresalier R; Xiang J
Gastroenterology; 1995 Dec; 109(6):1950-7. PubMed ID: 7498661
[TBL] [Abstract][Full Text] [Related]
5. Antibody-cytokine fusion proteins.
Kontermann RE
Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
[TBL] [Abstract][Full Text] [Related]
6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
7. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
Melief CJ
Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
[No Abstract] [Full Text] [Related]
8. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
[TBL] [Abstract][Full Text] [Related]
9. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
11. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
12. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
13. Antibody-directed, effector cell-mediated tumor destruction.
Sondel PM; Hank JA
Hematol Oncol Clin North Am; 2001 Aug; 15(4):703-21. PubMed ID: 11676280
[TBL] [Abstract][Full Text] [Related]
14. Advances in cancer immunotherapy.
Ockert D; Schmitz M; Hampl M; Rieber EP
Immunol Today; 1999 Feb; 20(2):63-5. PubMed ID: 10098323
[No Abstract] [Full Text] [Related]
15. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
16. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy for cancer.
Rosenberg SA
Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
[No Abstract] [Full Text] [Related]
18. [Current aspects and trends in immunotherapy of cancer].
Boniver J; Schaaf-Lafontaine N; Moutschen M; Longrée L; Lovens-Degraef D; Fassotte MF; Reginster MA; Simonet-Martin MT; Baudrihaye M
Rev Med Liege; 1990 Feb; 45(2):41-8. PubMed ID: 2138351
[No Abstract] [Full Text] [Related]
19. Circumvention of tumor cell escape following specific immunotherapy.
Frost P; Bonavida B
Cancer Biother Radiopharm; 2000 Apr; 15(2):141-52. PubMed ID: 10803319
[No Abstract] [Full Text] [Related]
20. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
